ARTICLE | Clinical News

Intuvax: Ph I/II data

December 30, 2016 1:19 AM UTC

Data from 6 evaluable HCC patients in an open-label, Swedish Phase I/II trial showed that second-line treatment with intratumoral Intuvax led to a median OS of 9.4 months. In 3 evaluable HCC patients ...

BCIQ Company Profiles

Mendus AB